Compare · ARYD vs GILD
ARYD vs GILD
Side-by-side comparison of ARYA Sciences Acquisition Corp IV (ARYD) and Gilead Sciences Inc. (GILD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARYD and GILD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $162.99B, about 862.5x ARYD ($189.0M).
- GILD has hit the wire 7 times in the past 4 weeks while ARYD has been quiet.
- GILD has more recent analyst coverage (25 ratings vs 0 for ARYD).
- Company
- ARYA Sciences Acquisition Corp IV
- Gilead Sciences Inc.
- Price
- $6.75-22.36%
- $131.23-1.11%
- Market cap
- $189.0M
- $162.99B
- 1M return
- -
- +3.91%
- 1Y return
- -
- +16.86%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 1992
- News (4w)
- 0
- 7
- Recent ratings
- 0
- 25
ARYA Sciences Acquisition Corp IV
ARYA Sciences Acquisition Corp IV focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded in 2020 and is based in New York, New York.
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Latest ARYD
- Adagio Medical Provides Business Updates
- SEC Form 15-12G filed by ARYA Sciences Acquisition Corp IV
- Chief Executive Officer Stone Adam Leo returned 499,000 units of Class A ordinary shares to the company (SEC Form 4)
- SEC Form 4 filed by Director Henderson Michael Thomas
- SEC Form 4 filed by Director Trigg Leslie
- SEC Form 4 filed by Director Edelman Joseph
- SEC Form 4 filed by Chief Business Officer Poukalov Konstantin
- SEC Form 4 filed by Director Wider Todd
- Large owner Arya Sciences Holdings Iv returned 499,000 units of Class A ordinary shares to the company (SEC Form 4)
- Chief Financial Officer Altman Michael Seth returned 499,000 units of Class A ordinary shares to the company (SEC Form 4)
Latest GILD
- FDA Approval for VEKLURY issued to GILEAD SCIENCES INC
- CHMP Recommends Gilead’s Trodelvy® Plus Keytruda® in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer
- Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
- Gilead Sciences downgraded by Leerink Partners with a new price target
- Chief Financial Officer Dickinson Andrew D sold $389,777 worth of shares (3,000 units at $129.93) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 168,646 units (SEC Form 4)
- Chief Comm & Corp Aff Officer Mercier Johanna sold $389,758 worth of shares (3,000 units at $129.92) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 121,234 units (SEC Form 4)
- Gilead Sciences upgraded by HSBC Securities with a new price target
- Chairman & CEO O'Day Daniel Patrick sold $1,894,400 worth of shares (15,000 units at $126.29) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 607,133 units (SEC Form 4)
- U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer
- Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market